Home
Obi Profile
Fees
Services
News
Publications
Contact
You are here:
Title Details
Search
Login
COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS
No-Receipt date
2022-02042 - 08/06/2022
No-Filing date
20220401181 - 08/06/2022
No-Granting date
3110571 - 06/07/2022
No-EPO application date
14805743.3 - 11/11/2014
No-EPO granting date
3068393 - 09/03/2022
Gazette No-Publication date of application
-
Gazette No-Publication date of granted patent
7/2022 - 08/08/2022
Expiration date
12/11/2034
Kind of title
Validation of European Patent
Legal status
NOT VALID
Priorities
US201361902717 P11/11/2013/US
Active Substance of Supplementary Certificates
-
IPC Classification
Ipc Class
A61P 35/02
A61K 31/7068
A61K 31/706
A61K 31/451
Related Documents
Related Titles
Owners
Code
Firstname
Surname
Address
Town
ZIP
Country
1411214
AMGEN INC.
ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CALIFORNIA 91320-1799
UNITED STATES OF AMERICA (USA)
Inventors
Code
Firstname
Surname
3637303
CAENEPEEL, SEAN
3637304
CANON, JUDE
3637305
HUGHES, PAUL
3637306
OLINER, JONATHAN D.
3637307
RICKLES, RICHARD J.
3637308
SAIKI, ANNE Y.
Representatives
Code
Firstname
Surname
Address
Town
Zip
3463
MARIA
ATHANASIADOU "ELENI G. PAPAKONSTANTINOU KAI SYNERGATES, DIKIGORIKI ETAIRIA"
KOUMPARI 2
ATHINA (ATTIKIS)
10674
Contact
Code
Firstname
Surname
Address
Town
Zip
Country
848
EFANGELIA
GIAZITZOGLOU - THOMAIDOU
KOUMPARI 2
ATHINA (ATTIKIS)
10674
GREECE
Owners History
Title Instruments
Date
Operation
Descreption
6/10/2024 12:00:00 AM
Έκπτωση Κύριων Τίτλων (79602)
ΕΚΠΤΩΣΕΙΣ 05/2024 Αρ. Πρωτ. ΓΔ 1758 / 10.06.2024
Payments history
9 renewals have been done
© OBI all rights reserved
designed & developed by PROFILE S.A.
Certified QMS :
EN ISO 9001:2015
and
ΕΝ ISO 14001:2015
The project "Internet technological information diffusion from industrial property titles" is co-financed 70% by the European Regional Development Found and 30% by the Hellenic public sector (Operational programme "Competitiveness", Measure 4.4).